JAMA Neurology Publishes Complete Results of Positive Phase 3 Study of REXULTI® (brexpiprazole) for

New efficacy data reported for pivotal Study 213 shows significant, clinically meaningful improvements in agitation symptoms.Agitation symptoms negatively impact functioning, disease progression, quality of life and care for about half of Alzheimer’s dementia patients – and are a consistent predictor of nursing home...

Related Keywords

Canada ,Mansfield ,Nunavut ,Italy ,United States ,Netherlands ,Tokyo ,Japan ,Lerdrup ,Midtjylland ,Denmark ,France ,Dutch ,John Kraus ,Robert Murphy ,Georget Grossberg ,Johan Luthman ,Lundbeck Pharmaceuticals ,Department Of Psychiatry ,Twitter ,Lundbeck ,Otsuka Holdings Co Ltd ,Corporate Communications ,Linkedin ,Otsuka America Pharmaceutical Inc ,Lundbeck Research Development ,National Pregnancy Registry For Atypical Antipsychotics ,Otsuka Pharmaceutical Company Ltd ,Health Canada ,International Psychogeriatric Association ,Otsuka Pharmaceutical Co Ltd ,European Medicines Agency ,Otsuka Pharmaceutical Development Commercialization Inc ,Drug Administration ,Ministry Of Health ,Otsuka Pharmaceutical Development ,Behavioral Neuroscience ,Saint Louis University School ,Mini Mental State Examination ,Cohen Mansfield Agitation Inventory ,Demonstrated Significant Efficacy ,Reducing Agitation ,Lundbeck Research ,Treatment Emergent Adverse Events ,Agitation Associated ,Dementia Due ,National Pregnancy Registry ,Otsuka America Pharmaceutical ,Otsuka Pharmaceutical Company ,Randomized Clinical ,Psychiatr Res ,Cohen Mansfield Agitation Inventory Observational ,Intj Geriatr Psychiatry ,Pharmacol Exp ,America Pharmaceutical ,